Sugi Predict

Sugi Predict / Compounds / SCHEMBL19359503

SCHEMBL19359503

SCHEMBL19359503

CC(C)(C)OC(=O)N[C@@H](CC(=O)OCc1ccccc1)C(=O)Nc1ccccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KLK7 P49862 2/20 0.56
▸ KLK5 Q9Y337 2/20 0.56
▸ CTSS P25774 5/20 0.48
▸ PPARA Q07869 3/20 0.48
▸ CTSK P43235 4/20 0.47
▸ CTSL P07711 3/20 0.47
▸ CTSB P07858 2/20 0.47
▸ MMP9 P14780 1/20 0.46
▸ SYK P43405 1/20 0.46
▸ PPARG P37231 2/20 0.44
▸ CACNA1B Q00975 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19359501 1.00 KLK7 (0.56) KLK7KLK5CTSSPPARACTSK
SCHEMBL19370941 0.92 KLK5 (0.54) KLK7KLK5CTSSPPARACTSK
SCHEMBL29743124 0.92 KLK5 (0.54) KLK7KLK5CTSSPPARACTSK
SCHEMBL7145073 0.92 CTSK (0.48) KLK7KLK5CTSSCTSKCTSL
SCHEMBL7145080 0.92 CTSK (0.48) KLK7KLK5CTSSCTSKCTSL
SCHEMBL7494181 0.86 CTSS (0.63) CTSSCTSKCTSLCTSB
SCHEMBL8432281 0.85 KLK5 (0.59) KLK7KLK5CTSSPPARACTSK
SCHEMBL28673199 0.84 KLK7 (0.53) KLK7KLK5CTSSPPARACTSK
SCHEMBL28673197 0.84 KLK7 (0.53) KLK7KLK5CTSSPPARACTSK
SCHEMBL15598266 0.83 CTSK (0.51) CTSSPPARACTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 — — US disclosed
CN-109153644-B Small molecules against CEREBLON to enhance effector T cell function H·李·莫菲特癌症中心研究有限公司 2022-10-21 — — CN disclosed
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-07-26 — — US disclosed
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-06-17 — — US disclosed
EP-3429996-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) 2019-01-23 — — EP disclosed
CN-109153644-A SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H·李·莫菲特癌症中心研究有限公司 2019-01-04 — — CN disclosed
WO-2017161119-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11395820-B2 Small molecules against cereblon to enhance effector t cell function CD4, GZMB, CRBN KLK7 2354/4885KLK5 3755/4885CTSS 330/4885
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, CRBN, GZMB KLK7 2885/4885KLK5 4238/4885CTSS 107/4885
US-20210177825-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, GZMB, CRBN KLK7 2354/4885KLK5 3755/4885CTSS 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.